Takashi Sonoki

Prof. Dr. Takashi Sonoki


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2011 in Leukemia
Verified
Journal Article
Open access
PDF file
YEY Enomoto
Y Enomoto
JKJ Kitaura
J Kitaura
KHK Hatakeyama
K Hatakeyama
JWJ Watanuki
J Watanuki
TAT Akasaka
T Akasaka
TSTakashi Sonoki
Takashi Sonoki
MicroRNA-125b-1 (miR-125b-1) is a target of a chromosomal translocation t(11;14)(q24;q32) recurrently found in human B-cell precursor acute lymphoblastic leukemia (BCP-ALL). This translocation results in overexpression of miR-125b controlled by immunoglobulin heavy chain gene (IGH) regulatory elements. In addition, we found that six out of twenty-one BCP-ALL patients without t(11;14)(q24;q32) showed overexpression of miR-125b. Interestingly, four out of nine patients with BCR/ABL-positive BCP-ALL and one patient with B-cell lymphoid crisis that had progressed from chronic myelogenous leukemia overexpressed miR-125b. To examine the role of the deregulated expression of miR-125b in the development of B-cell tumor in vivo, we generated transgenic mice mimicking the t(11;14)(q24;q32) (Eμ/miR-125b-TG mice). Eμ/miR-125b-TG mice overexpressed miR-125b driven by IGH enhancer and promoter and developed IgM-negative or IgM-positive lethal B-cell malignancies with clonal proliferation. B cells obtained from the Eμ/miR-125b-TG mice were resistant to apoptosis induced by serum starvation. We identified Trp53inp1, a pro-apoptotic gene induced by cell stress, as a novel target gene of miR-125b in hematopoietic cells in vitro and in vivo. Our results provide direct evidence that miR-125b has important roles in the tumorigenesis of precursor B cells.

Verified
Journal Article
Open access
PDF file
YYYusuke Yamashita
Yusuke Yamashita
SMShuhei Morita
Shuhei Morita
HHHiroki Hosoi
Hiroki Hosoi
HKHiroshi Kobata
Hiroshi Kobata
SKShohei Kishimoto
Shohei Kishimoto
STShinobu Tamura
Shinobu Tamura
Background: Inositol-requiring enzyme 1α (IRE1α), along with protein kinase R-like endoplasmic reticulum kinase (PERK), is a principal regulator of the unfolded protein response (UPR). Recently, the ‘mono’-specific IRE1α inhibitor, kinase-inhibiting RNase attenuator 6 (KIRA6), demonstrated a promising effect against multiple myeloma (MM). Side-stepping the clinical translation, a detailed UPR phenotype in patients with MM and the mechanisms of how KIRA8 works in MM remains unclear. Methods: We characterized UPR phenotypes in the bone marrow of patients with newly diagnosed MM. Then, in human MM cells we analyzed the possible anti-tumor mechanisms of KIRA8 and a Food and Drug Administration (FDA)-approved drug, nilotinib, which we recently identified as having a strong inhibitory effect against IRE1α activity. Finally, we performed an RNA-sequence analysis to detect key IRE1α-related molecules against MM. Results: We illustrated the dominant induction of adaptive UPR markers under IRE1α over the PERK pathway in patients with MM. In human MM cells, KIRA8 decreased cell viability and induced apoptosis, along with the induction of C/EBP homologous protein (CHOP); its combination with bortezomib exhibited more anti-myeloma effects than KIRA8 alone. Nilotinib exerted a similar effect compared with KIRA8. RNA-sequencing identified Polo-like kinase 2 (PLK2) as a KIRA8-suppressed gene. Specifically, the IRE1α overexpression induced PLK2 expression, which was decreased by KIRA8. KIRA8 and PLK2 inhibition exerted anti-myeloma effects with apoptosis induction and the regulation of cell proliferation. Finally, PLK2 was pathologically confirmed to be highly expressed in patients with MM. Conclusion: Dominant activation of adaptive IRE1α was established in patients with MM. Both KIRA8 and nilotinib exhibited anti-myeloma effects, which were enhanced by bortezomib. Adaptive IRE1α signaling and PLK2 could be potential therapeutic targets and biomarkers in MM.

31 March 2009 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
TSTakashi Sonoki
Takashi Sonoki
YLYaqiong Li
Yaqiong Li
SMSetsuko Miyanishi
Setsuko Miyanishi
HNHirokazu Nakamine
Hirokazu Nakamine
NHNobuyoshi Hanaoka
Nobuyoshi Hanaoka
HNHideki Nakakuma
Hideki Nakakuma

1 March 2021 in Gene
Verified
Journal Article
Closed access
HHHiroki Hosoi
Hiroki Hosoi
ANAkiko Niibori-Nambu
Akiko Niibori-Nambu
GNGiselle Sek Suan Nah
Giselle Sek Suan Nah
ABAvinash Govind Bahirvani
Avinash Govind Bahirvani
MMMichelle Meng Huang Mok
Michelle Meng Huang Mok
MOMotomi Osato
Motomi Osato

1 August 2007 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
TSTakashi Sonoki
Takashi Sonoki
HTHiro Tatetsu
Hiro Tatetsu
ANAkitoshi Nagasaki
Akitoshi Nagasaki
HHHiroyuki Hata
Hiroyuki Hata

22 February 2024 in Leukemia Research Reports
Verified
Journal Article
Open access
HHHiroki Hosoi
Hiroki Hosoi
STShotaro Tabata
Shotaro Tabata
HKHideki Kosako
Hideki Kosako
YHYoshikazu Hori
Yoshikazu Hori
TOTadashi Okamura
Tadashi Okamura
TSTakashi Sonoki
Takashi Sonoki
IGLL5 is shown to be located near super-enhancer (SE) in B-cell tumors, and this gene is frequently mutated and a target of translocation in B-cell tumors. These results suggest roles of the IGLL5 in tumorigenesis; however, its functional properties have been unclear. We found that two mature B-cell lymphoma cell lines expressed IGLL5 mRNA with C lambda 1 segment. JQ1 treatment resulted in down-expression of IGLL5, indicating that IGLL5 is controlled by SE. IGLL5 knockdown induced cell death with down-expression of MYC. Our results suggested that IGLL5 might have a role in survival of mature B-cell tumors and involvement in MYC expression. (100 words)